Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Bjerre Trent P, Leitzinger N, Wang Y, Dahl GF, Eyjólfsdóttir B, Dahl JF, Lund KV, Staff AC, Falk RS, Eriksson AGZ(2025) The detection rate of metastatic lymph nodes comparing sentinel lymph node biopsy and lymphadenectomy for staging of intermediate- and high-risk endometrial carcinoma Int J Gynecol Cancer, 35(5), 101810(in press) DOI 10.1016/j.ijgc.2025.101810, PubMed 40288097
Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K(2025) Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study Acta Oncol, 64, 439-447 DOI 10.2340/1651-226X.2025.43045, PubMed 40105683
Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C(2025) First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer J Nucl Med(in press) DOI 10.2967/jnumed.124.269299, PubMed 40081958
